Coeptis Therapeutics Holdings, Inc. - COEP STOCK NEWS

Coeptis Therapeutics Holdings (Nasdaq: COEP), a biopharmaceutical firm, announced that Dr. Colleen Delaney, Chief Scientific and Medical Officer, will present at the Allogeneic Cell Therapies Summit 6th Annual Meeting in Boston from June 10-12, 2024.

Dr. Delaney will deliver two key seminars on June 10: a panel discussion at 4:00 PM on the ideal starting materials for allogeneic products and a session at 5:30 PM on overcoming hurdles in allogeneic cell therapy using pooled donor cord blood CD34+ cells.

The Summit gathers leaders to discuss the future of allogeneic cell therapies, providing Coeptis with a platform to share its progress and innovations, especially with its universal SNAP-CAR technology aimed at reshaping cancer treatment.

Coeptis Therapeutics Holdings, a biopharmaceutical company, will present its innovative universal allogeneic SNAP-CAR NK cell therapy at the ISCT 2024 conference. This therapy has the potential to target multiple antigens, potentially avoiding toxicities and relapse. Coeptis expanded its license agreement for SNAP-CAR to include natural killer cells, aiming to develop a safer and cost-effective cellular therapy. The company's presentation at ISCT 2024 signifies a significant step towards universalizing the treatment of various diseases.

Coeptis Therapeutics Holdings, a biopharmaceutical company, will present data on the development of SNAP-CAR NK cells at the ASGCT Annual Meeting. The Company aims to revolutionize cancer treatment with a universal targeted cell therapy that eliminates the need for HLA matching.

Coeptis Therapeutics congratulates Professor Deiters for receiving the University of Pittsburgh's 2024 Chancellor's Distinguished Research Award for his innovative CAR T cell therapy platform. The company aims to revolutionize oncology and autoimmune disorder treatments with SNAP-CAR technology.

Coeptis Therapeutics Holdings, Inc. expands its exclusive license agreement with the University of Pittsburgh to include autoimmune indications for its SNAP-CAR T and SNAP-CAR NK cell therapy platforms. The technology has the potential to target multiple antigens simultaneously, impacting autoimmune diseases and oncology indications.

Coeptis Therapeutics Holdings, Inc. announces plans to pursue DVX201, a novel allogeneic stem cell expansion and directed differentiation platform of unmodified natural killer (NK) cell therapy, as an antiviral treatment for severe respiratory viral infections, including influenza, COVID-19, and respiratory syncytial virus (RSV). The therapy aims to replenish immune cells to help fight the infection and has shown promising results in Phase 1 clinical trials for patients with COVID-19 and hematological malignancies.

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced President and CEO Dave Mehalick's Letter to Shareholders, detailing the exclusive licensing agreement with Deverra Therapeutics Inc, the progress of DVX201 allogeneic NK cell therapy, and the company's vision for developing next-generation cell therapy technologies for cancer and infectious diseases.

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced that Dave Mehalick, President and CEO, will deliver a virtual presentation at the Emerging Growth Conference on December 6th, 2023. Coeptis is a biopharmaceutical company developing innovative cell therapy platforms for cancer.

Coeptis Therapeutics announces research demonstrating the potential of the SNAP-CAR T-cell platform to target multiple antigens through combinatorial use of different adaptors. The research shows versatile antigen targeting abilities in vitro and in vivo, including potent and specific function, tumor reduction, and inhibition of tumor growth. The findings suggest the SNAP-CAR platform has vast potential for treating various cancers.